Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilance
Scientific Writing
Other
About us
Search
CLINSQUARE: CLINICAL RESEARCH COURSES
Friday, May 9, 2025
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilance
Scientific Writing
Other
About us
Facebook
Twitter
CLINSQUARE: Clinical Rsearch Courses by LIFEPRONOW
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilance
Scientific Writing
Other
About us
Search
Tags
Dupixent® (dupilumab)
Tag:
Dupixent® (dupilumab)
Latest Pharma-News
Second Dupixent Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements
admin
-
October 25, 2021
0
Latest Pharma-News
Sanofi’s Dupixent® significantly improved itch and hives in chronic spontaneous urticaria
admin
-
July 29, 2021
0
Latest Pharma-News
Dupixent® SmPC updated safety profile with moderate-to-severe atopic dermatitis
admin
-
June 28, 2021
0
Latest Pharma-News
FDA accepts for priority review Sanofi’s Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis
admin
-
January 28, 2020
0
- Advertisment -
Most Read
J&J announced Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin
April 11, 2025
Sanofi’s Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
April 9, 2025
Novartis receives FDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy
April 9, 2025
AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025
April 9, 2025